The main secondary goal ( cardiovascular death , myocardial infarction , vascular stroke , hospitalisation for a heart failure or angina pectoris and myocardial revascularisation ) occurred in @ % ( @,@ ) patients treated with saxagliptin and in @ % ( @,@ ) patients treated with placebo .